<DOC>
	<DOCNO>NCT02103114</DOCNO>
	<brief_summary>The purpose study test whether administration ATIII intra-operative period result improved anticoagulation cardiopulmonary bypass ( CPB ) attenuation activation coagulation cascade , represent decrease fibrin degradation product . The investigator believe benefit would extend post-operative period result decreased incidence thrombosis generation , represent decrease fibrin degradation product ICU period .</brief_summary>
	<brief_title>Anti-thrombin III ( ATIII ) v Placebo Children ( &lt; 7mo ) Undergoing Open Congenital Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Antithrombin III Deficiency</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>All patient le 7 month age go cardiac surgery require cardiopulmonary bypass ( CPB ) document ATIII level 70 % Less 2.5kg Known suspect hereditary ATIII deficiency ( family history venous thrombosis decrease plasma level ATIII potential cause acquire decreased ATIII ) On Ecmo ( extracorporeal membrane oxygenation ) time surgery Known history thrombosis Renal failure describe pediatric RIFLE criterion H/o intracranial hemorrhage Prematurity le 37 week estimate gestational age Previously diagnose prothrombotic hemorrhagic disorder Prior ATIII supplementation Prior therapeutic anticoagulant use</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>